Questions? Chat with the founder on WhatsApp

Chat with the founder on WhatsApp
Arthneeti
HomeRankingsIPOScreenerInstitutions
HomeRankingsIPOScreenerInstitutions
Nephrocare Health Services LtdQ1 FY27Healthcare Services
Home/Stocks/Nephrocare Health Services Ltd/Q1 FY27

Nephrocare Health Services Ltd Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹694P/E: 82.0Market Cap: ₹7.0K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
- Focus on platform-level ROCE-accretive investments rather than country-level details; currently in 5 countries, aiming for 10-15 countries in 5-10 years. - Growth driven by three levers: 1. Same center growth (increased utilization) 2. Increasing footprint in existing markets (adding new clinics) 3. Market expansion via new countries, M&A, and Public-Private Partnerships (PPP). - Target to open 40-50 clinics annually in India, 10-15 clinics annually in the Philippines, and enter a new international market every 12-18 months. - Network utilization is key; capacity addition is essential since dialysis machines have fixed treatment cycles limiting volume growth without new centers. - International operations contribute around 45% of revenue, reflecting their growing importance in overall growth. - The business expects sustained long-term growth through disciplined capacity addition, new market entries, and leveraging the scalable operating platform.

Margin guidance

Category 3
  • →Nephrocare Health Services Limited maintains a **medium-term growth guidance of 15% to 20% CAGR** over the next 3 to 5 years.
  • →Growth levers include **organic same-center growth, footprint expansion in existing markets, and new market entry via acquisitions and PPPs**.
  • →Focus on **disciplined capacity addition**, as dialysis growth is driven by adding new centers due to fixed machine cycle limits.
  • →Expansion to increase clinics by **40-50 annually in India and 10-15 in the Philippines**, with entry into a new international market every 12-18 months.
  • →Adjusted EBITDA margin improving (23.1% in Q1 FY27), reflecting **operating leverage and international market contribution**.
  • →Emphasis on **capital-efficient growth** with annualized adjusted ROCE at 21% in Q1 FY27.
  • →Investment phase in markets like Saudi expected to impact near-term losses but aimed for medium- to long-term profitability.

Track Nephrocare Health Services Ltd — get its next earnings analysis in your feed

Fundraise plans

  • →No explicit mention of current or planned new fundraising through debt or equity in the provided excerpts.
  • →The company has utilized 68% (~INR 207 crores) of the IPO proceeds for expanding network, acquisitions, and loan repayments as of June 2026.
  • →They continue to focus on disciplined capital allocation and capital-efficient growth.
  • →Saudi Arabia expansion is in an investment phase dependent on tender outcomes; potential future investments based on tender wins.
  • →International expansion is ongoing, with investments in new markets like the EU region and Kazakhstan exploration, but no specific funding plans disclosed.
  • →Overall, the emphasis is on using existing capital (including IPO proceeds) for growth rather than new fundraising at this point.

Order book

The provided pages of the Nephrocare Health Services Limited document do not explicitly mention details about the current or expected order book or pending orders. However, some relevant points related to future growth and investments include: - The company anticipates expanding from 5 countries to 10-15 countries over the next 5 to 10 years. - Growth is driven by three levers: same center growth, footprint expansion in existing markets, and market expansion including M&A and PPP. - Saudi Arabia market entry depends on winning a nationwide tender, which will determine the number of clinics established. - The newly incorporated EU subsidiary is exploring potential markets like Kazakhstan but no definitive plans yet. - Planned clinic additions: 40-50 in India annually, 10-15 in the Philippines annually, with new international markets approximately every 12-18 months. No specific order book figures or pending orders are disclosed in the excerpts.

Capex plans

Yes
  • →Capital expenditure for Q1 FY27 was INR44 crores towards center acquisitions and growth.
  • →The company intends to open 40 to 50 clinics in India and 10 to 15 clinics in the Philippines every year.
  • →Plans to enter a new international market every 12 to 18 months.
  • →Focus on disciplined capital allocation ensuring investments are ROCE accretive at the platform level.
  • →Current investments include expanding the network, pursuing center acquisitions in both India and international markets, and paying off term loans.
  • →Saudi Arabia operations are currently in an investment phase, setting up clinics to qualify for tenders; future investments depend on tender outcomes.
  • →Continue investing in strengthening technology platforms and clinical quality.

How does Nephrocare Health Services Ltd rank vs peers in Healthcare Services?

Pro feature
1Nephrocare Health Services Ltd
Rev 2Mar 3
2Healthcare Services Company A
Rev 1Mar 2
3Healthcare Services Company B
Rev 2Mar 1
4Healthcare Services Company C
Rev 2Mar 3

See full Healthcare Services sector rankings

How does Nephrocare Health Services Ltd rank in Healthcare Services?

Compare Nephrocare Health Services Ltd against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Related research

Read the full Q1 FY27 earnings insight — Nephrocare Health Services Ltd

Other quarters — Nephrocare Health Services Ltd

Q4 FY26Q3 FY26

Healthcare Services peers

Apollo Hospitals Enterprise Ltd · Q4 FY26Fortis Health. · Q1 FY27Syngene International Ltd · Q4 FY26Dr Lal Pathlabs · Q1 FY27Narayana Hrudaya · Q1 FY27
Nephrocare Health Services Ltd full stock analysisHealthcare Services sectorEarnings call directoryRankings dashboard

Questions about this analysis? Chat directly with the founder — real answers about the research, not a support bot.

WhatsApp the founder

Research team or advisory firm? Get earnings-call intelligence and ranking history as research inputs for your firm.

For Institutions

Arthneeti AI

AI-powered stock analysis from earnings call transcripts. Helping Indian investors make smarter decisions with data-driven insights.

Analysis

  • Stock Rankings
  • Sectors
  • Compare Stocks
  • IPO Dashboard
  • Stock Screener
  • Earnings Call Analysis
  • Stocks Under ₹500
  • Multibaggers

Tools

  • MF Overlap Checker
  • SIP Calculator
  • CAGR Calculator
  • FD vs Equity
  • All Calculators

Resources

  • Blog
  • Weekly Digest
  • Portfolio Analysis
  • Build Portfolio
  • Earnings Calendar
  • Q1 FY27 Earnings Hub

Company

  • Pricing
  • How Our Analysis Works
  • For Institutions
  • Terms of Service
  • Privacy Policy

Compare

  • vs Screener.in
  • vs Trendlyne
  • vs Tickertape
  • vs Moneycontrol Pro
+91 90841 32575 support@arthneeti.com Bengaluru, India

© 2026 Arthneeti AI. All rights reserved.

AI-analyzed data from 1,500+ company earnings calls

Continue your research

What Nephrocare Health Services Ltd's management said in earlier quarters

  • Q1 FY27 earnings call analysis →
  • Q3 FY26 earnings call analysis →
  • Q4 FY26 earnings call analysis →

Others in Healthcare Services this season

  • Rainbow Childrens Medicare Ltd (Q3 FY25)

    Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…

  • Dr Lal Pathlabs (Q3 FY25)

    Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…

  • Apollo Hospitals Enterprise Ltd (Q4 FY25)

    . Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Shalby Ltd (Q4 FY25)

    Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…

Compare:vs Apollo Hospitals Enterprise Ltdvs Max Healthcarevs Fortis Health.